Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 13/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262145 | 0.83 | TACR1 (0.48) | TACR1CCR2 | |
| SCHEMBL1420423 | 0.70 | KMT2A (0.53) | TRPV4TSHRKMT2ACCR2 | |
| Hydrochloric Acid SCHEMBL6512689 | 0.69 | TRPV4 (0.58) | TRPV4TACR1 | |
| SCHEMBL24183601 | 0.68 | TRPV4 (0.51) | TRPV4TACR1TSHRKMT2ANPY2R | |
| SCHEMBL24183606 | 0.66 | HDAC3 (0.48) | TRPV4KMT2A | |
| SCHEMBL12552673 | 0.65 | RBP4 (0.48) | KMT2A | |
| SCHEMBL5317188 | 0.65 | TACR1 (0.78) | TACR1 | |
| SCHEMBL14503410 | 0.65 | CASP1 (0.54) | TSHRKMT2A | |
| SCHEMBL4257753 | 0.64 | L3MBTL1 (0.50) | — | |
| SCHEMBL1961881 | 0.64 | CSF1R (0.47) | TRPV4NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1473295-B1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-6995153-B2 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL. CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1473295-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | BDKRB1, BDKRB2, TACR1 | TRPV4 221/4885TACR1 3/4885TSHR 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.